Cell Source, Inc.
CLCS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$36M
Close$
$-0.23
149.5% downside
Current Fair Value
149.5% downsideOvervalued by 149.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $36.00 Million |
|---|---|
| Enterprise Value | $46.00 Million |
| Earnings per Share | $-0.1 |
| Beta | -157.98 |
| Outstanding Shares | 45,038,244 |
Return
| Return on Equity | 25.38% |
|---|---|
| Return on Assets | -1665.17% |
| Return on Invested Capital | 19.17% |
Valuation & Multiples
| P/E Ratio | -5.3 |
|---|---|
| PEG | 12.09 |
| Price to Sales | - |
| Price to Book Ratio | -0.47 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -12.77 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | -0.54 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cell Source, Inc.
1 employees
CEO: Itamar Shimrat
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tole...